CTNI-23. IDH1/2wt ANAPLASTIC GLIOMAS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL: OVERALL SURVIVAL RELATED TO TREATMENT, MGMT STATUS AND MOLECULAR FEATURES OF GLIOBLASTOMA
C. Mircea S. Tesileanu(Erasmus MC Cancer Institute), Martin J. van den Bent(Erasmus MC Cancer Institute), Kenneth Aldape(National Cancer Institute), Anna K. Nowak(The University of Western Australia), Michael Weller(University Hospital of Zurich), Pim J. French(Erasmus MC Cancer Institute), S. C. Erridge(Western General Hospital), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Pieter Wesseling(Radboud University Nijmegen), Helen Wheeler(The University of Sydney), Marc Sanson(Centre National de la Recherche Scientifique), Johan M. Kros(Erasmus MC), Brigitta G. Baumert(Kantonsspital Graubünden), Wolfgang Wick(German Cancer Research Center), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Jean Français Baurain(Cliniques Universitaires Saint-Luc), Vassilis Golfinopoulos(Champalimaud Foundation), Paul M. Clément(Universitair Ziekenhuis Leuven), Michael A. Vogelbaum(Moffitt Cancer Center), Warren Mason(Princess Margaret Cancer Centre)
Cited by 1
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Paraneoplastic anti– <i>N</i> ‐methyl‐ <scp>D</scp> ‐aspartate receptor encephalitis associated with ovarian teratoma
|Annals of Neurology|2007|2.5k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
|Journal of Clinical Oncology|2010|2k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k